Tags:Motavizumab 代理商,Motavizumab 价格,Motavizumab 供应商, Motavizumab supplier,Motavizumab purchase,Motavizumab 购买,Motavizumab 销售
Description
Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .
Catalog No.
DVV02803
Host species
Humanized
Species reactivity
HRSV-A
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
3.06 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, kappa
Applications
Research Grade Biosimilar
Target
F, Fusion glycoprotein F0
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P03420
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
MEDI-524,NUMAX, NISTmAb, CR9503, CAS: 677010-34-3, Human Respiratory Syncytial Virus (HRSV)
Note
For research use only. Not suitable for clinical or therapeutic use.
关键字: Motavizumab;莫维组单抗;677010-34-3;F;
武汉佰乐博生物(Biolab?Reagents)由一群具有二十年工作经验的生命科学领域顶级研究者创立于2021年,凭借丰富的产品开发经验,利用全球领先的技术平台,引进和整合全球高品质的蛋白、抗体和试剂盒产品。目前,佰乐博生物作为法国AntibodySystem和ProteoGenix在亚洲的独家总代理,提供近30,000种生命科学试剂,核心产品涵盖蛋白、抗体和试剂盒,旨在为科研工作者提供专业、全面、可靠的试剂支持,推动生命科学研究的深入发展。